Conduit Pharmaceuticals Stock Performance
| CDT Stock | 1.28 0.03 2.29% |
The firm shows a Beta (market volatility) of 4.31, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Conduit Pharmaceuticals will likely underperform. At this point, Conduit Pharmaceuticals has a negative expected return of -1.97%. Please make sure to confirm Conduit Pharmaceuticals' potential upside, as well as the relationship between the rate of daily change and relative strength index , to decide if Conduit Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Conduit Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's fundamental indicators remain comparatively stable which may send shares a bit higher in January 2026. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
Last Split Factor 1:8 | Last Split Date 2025-10-13 |
1 | Conduit Pharmaceuticals Announces Reverse Stock Split - TipRanks | 10/10/2025 |
2 | Is Conduit Pharmaceuticals Inc. stock supported by strong cash flows - 2025 Price Targets Low Risk Growth Stock Ideas - newser.com | 10/29/2025 |
3 | Is Conduit Pharmaceuticals Inc. Equity Warrant stock overvalued by current metrics - July 2025 Opening Moves Safe Entry Point Alerts - newser.com | 11/05/2025 |
4 | How Conduit Pharmaceuticals Inc. stock responds to bond market - July 2025 Highlights Risk Managed Investment Strategies - newser.com | 11/10/2025 |
5 | Is Conduit Pharmaceuticals Inc. Equity Warrant stock overvalued by current metrics - Gap Down Stepwise Trade Signal Implementation - newser.com | 11/14/2025 |
6 | How risky is Conduit Pharmaceuticals Inc. stock compared to peers - Stop Loss Verified Stock Trade Ideas - newser.com | 11/17/2025 |
7 | What drives Conduit Pharmaceuticals Inc Equity Warrant stock price - Fundamental Strength Indicators Build Wealth With Expert Timing Advice - earlytimes.in | 11/21/2025 |
8 | Disposition of 200000 shares by Kuznik Ferdinand of Conduit Pharmaceuticals at 14.25 subject to Rule 16b-3 | 11/25/2025 |
9 | CDT Environmental Technology Announces Results of Annual General Meeting | 11/28/2025 |
10 | Published on 2025-12-05 045309 - Newser | 12/05/2025 |
11 | Acquisition by Andrew Regan of 224800 shares of Conduit Pharmaceuticals at 1.79 subject to Rule 16b-3 | 12/08/2025 |
12 | Can Conduit Pharmaceuticals Inc. stock double in next 5 years - Market Trend Review Target Return Focused Picks - DonanmHaber | 12/19/2025 |
| Begin Period Cash Flow | 4.2 M | |
| Total Cashflows From Investing Activities | -43 K | |
| Free Cash Flow | -9.7 M |
Conduit Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 543.00 in Conduit Pharmaceuticals on October 2, 2025 and sell it today you would lose (415.00) from holding Conduit Pharmaceuticals or give up 76.43% of portfolio value over 90 days. Conduit Pharmaceuticals is generating negative expected returns assuming volatility of 7.7009% on return distribution over 90 days investment horizon. In other words, 69% of stocks are less volatile than Conduit, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Conduit Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Conduit Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Conduit Pharmaceuticals, and traders can use it to determine the average amount a Conduit Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2556
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CDT |
Based on monthly moving average Conduit Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Conduit Pharmaceuticals by adding Conduit Pharmaceuticals to a well-diversified portfolio.
Conduit Pharmaceuticals Fundamentals Growth
Conduit Stock prices reflect investors' perceptions of the future prospects and financial health of Conduit Pharmaceuticals, and Conduit Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Conduit Stock performance.
| Return On Asset | -2.07 | ||||
| Current Valuation | 171.52 K | ||||
| Shares Outstanding | 1.35 M | ||||
| Price To Book | 0.54 X | ||||
| Revenue | 922.22 M | ||||
| EBITDA | (15.84 M) | ||||
| Net Income | (17.8 M) | ||||
| Total Debt | 7.46 M | ||||
| Book Value Per Share | 3.35 X | ||||
| Cash Flow From Operations | (9.68 M) | ||||
| Earnings Per Share | (179.34) X | ||||
| Market Capitalization | 1.77 M | ||||
| Total Asset | 4.19 M | ||||
| Retained Earnings | (29.1 M) | ||||
| Working Capital | (8.03 M) | ||||
About Conduit Pharmaceuticals Performance
Assessing Conduit Pharmaceuticals' fundamental ratios provides investors with valuable insights into Conduit Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Conduit Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.01 | 0.01 | |
| Return On Capital Employed | 2.35 | 2.47 | |
| Return On Assets | (4.25) | (4.46) | |
| Return On Equity | 2.62 | 2.75 |
Things to note about Conduit Pharmaceuticals performance evaluation
Checking the ongoing alerts about Conduit Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Conduit Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Conduit Pharmaceuticals generated a negative expected return over the last 90 days | |
| Conduit Pharmaceuticals has high historical volatility and very poor performance | |
| Conduit Pharmaceuticals may become a speculative penny stock | |
| Conduit Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the last year's revenue of 922.22 M. Reported Net Loss for the year was (17.8 M) with profit before taxes, overhead, and interest of 0. | |
| Conduit Pharmaceuticals generates negative cash flow from operations | |
| Conduit Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| About 29.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Can Conduit Pharmaceuticals Inc. stock double in next 5 years - Market Trend Review Target Return Focused Picks - DonanmHaber |
- Analyzing Conduit Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Conduit Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Conduit Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Conduit Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Conduit Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Conduit Pharmaceuticals' stock. These opinions can provide insight into Conduit Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Conduit Stock Analysis
When running Conduit Pharmaceuticals' price analysis, check to measure Conduit Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Conduit Pharmaceuticals is operating at the current time. Most of Conduit Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Conduit Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Conduit Pharmaceuticals' price. Additionally, you may evaluate how the addition of Conduit Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.